Vaxil Completes Oversubscribed Financing to Advance Its Cancer Immunotherapy Research and Development – Marketwired (press release)
|
Vaxil Completes Oversubscribed Financing to Advance Its Cancer Immunotherapy Research and Development
Marketwired (press release) NESS-ZIONA, ISRAEL–(Marketwired – January 30, 2018) – VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli cancer immunotherapy company, is pleased to announce the closing of an oversubscribed equity financing of $1,810,000 (the "Financing"). "We … |
